Sector ratings Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq 06:00:00 12/09/26 am AEST			5-day change	1st Jan Change
32.47 ^USD	+0.74%		-3.36%	+5.42%

08/09	Espiria Hållbar Framtid rose 4.5 percent in August, Vestas and Hansa Biopharma made positive contributions	FW
08/09	Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN	FW

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation
WUXI APPTEC CO., LTD.	66.93B		AAA
ARGENX SE	61.97B		A
INSMED INCORPORATED	28.26B	-	BBB	-		-
WUXI BIOLOGICS (CAYMAN) INC.	24.59B		AAA
BIONTECH SE	24.3B	-	-	-		-
GENMAB A/S	19.41B		A
PHARMAESSENTIA CORPORATION	16.77B		AA
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	14.18B		AA
SUMMIT THERAPEUTICS INC.	14B	-	-	-		-
EXELIXIS, INC.	13.91B		BB
MADRIGAL PHARMACEUTICALS, INC.	12.35B	-	B	-		-
ARROWHEAD PHARMACEUTICALS, INC.	11.7B	-	BB	-		-
AKESO, INC.	10.61B		B			-
CYTOKINETICS, INCORPORATED	10.26B	-	AA	-		-
VAXCYTE, INC.	8.85B	-	BBB	-		-
IMMUNITYBIO, INC.	8.38B	-	CCC	-		-
REMEGEN CO., LTD.	8B		-
SPYRE THERAPEUTICS, INC.	7.99B	-	BB	-	-	-
BELITE BIO, INC	7B	-	-	-		-
Average	19.45B		A
Weighted average by Cap.			A